Genetic and nongenetic factors influencing pharmacokinetics of B-type Natriuretic peptide

Journal of Cardiac Failure

Volumn 20, Issue 9, 2014, Pages 662-668

  Lanfear, David E ^a   Chow, Sheryl ^a   Padhukasahasram, Badri ^a   Li, Jia ^a   Langholz, David ^a   Tang, W H Wilson ^a   Williams, L Keoki ^a   Sabbah, Hani N ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Drug metabolism; Genetic polymorphisms; Heart failure; Natriuretic peptide; Pharmacogenetics

Indexed keywords

NESIRITIDE; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR C; RECOMBINANT PROTEIN;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; CONTINUOUS INFUSION; DRUG CLEARANCE; ELIMINATION RATE CONSTANT; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; HEART STROKE VOLUME; MIDDLE AGED; PROSPECTIVE STUDY;

FEMALE; GENOTYPE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RECOMBINANT PROTEINS; STROKE VOLUME;

EID: 84926309989     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.06.357     Document Type: Article

References (26)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statisticsd2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220.
2. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135(5 Pt 1):825-32.
3. Ellmers LJ, Scott NJ, Piuhola J, Maeda N, Smithies O, Frampton CM, et al. Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 2007;38:245-57.
4. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
5. Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordonez-Llanos J, Martinez P, et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008;29:1011-8.
6. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
7. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
8. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
9. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-95.
10. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91.
11. Lanfear DE. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev 2010;15:219-28.
12. Cannone V, Huntley BK, Olson TM, Heublein DM, Scott CG, Bailey KR, et al. Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension 2013;62:860-5.
13. Cannone V, Cefalu AB, Noto D, Scott CG, Bailey KR, Cavera G, et al. The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a mediterranean population. Diabetes Care 2013;36:2850-6.
14. Lanfear DE, Sunkara B, Li J, Rastogi S, Gupta RC, Padhukasahasram B, et al. Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res 2013;6:826-33.
15. Pereira NL, Lin D, Pelleymounter L, Moon I, Stilling G, Eckloff BW, et al. Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation. Circ Cardiovasc Genet 2013;6:201-10.
16. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 2007;21:55-62.
17. Lanfear DE, Stolker J, Marsh S, Rich MW, McLeod HL. Natriuretic peptide receptor 3 (NPR3) genotype modulates the relationship between B-type natriuretic peptide (BNP) and left ventricular enddiastolic pressure. Therapy 2006;3:765-71.
18. Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, Mahoney DW, Slusser JP, Heublein DM, et al. The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc 2011;86:210-8.
19. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarkerguided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158:422-30.
20. Luss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Moiseyev VS, et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008;155:1012. e1ee8.
21. McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep 2010;7:93-9.
22. Wu AH, Packer M, Smith A, Bijou R, Fink D, Mair J, et al. Analytical and clinical evaluation of the Bayer Advia Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 2004;50:867-73.
23. Food and Drug Administration. Nesiritide prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/020920s031lbl.pdf.
24. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9.
25. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84.
26. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798-803.